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Clink, 1957; Wadenberg and Hicks, 1999). This selective 
disruption of avoidance but not escape most likely reflects 
the interactions between the characteristic pharmacologi-
cal properties of antipsychotics and experimental factors 
related to differences in scheduling of events and patterns of 
behavioral responding (Spealman et al., 1983; Barrett, 2002; 
McMillan and Katz, 2002). Regardless of the nature of this 
selective disruption on avoidance responding, this feature 
has been effectively used to differentiate APDs from other 
classes of psychotropic drugs (e.g. anxiolytics and antide-
pressants, which lack this selectivity on avoidance vs. escape 
responses); to predict clinical potencies of APDs (potencies in 
the CAR test correlate with clinical potencies); and to identify 
potential APDs (Janssen et al., 1965; Bignami, 1978; Cook and 
Davidson, 1978; Kuribara and Tadokoro, 1981; Arnt, 1982; 
Van der Heyden and Bradford, 1988; Shannon et al., 1999; 
Wadenberg and Hicks, 1999). Therefore, understanding the 
nature of APD-induced avoidance decreases may shed light 
on the behavioral mechanism of antipsychotic action in the 
treatment of psychosis in patients with schizophrenia.
Published in Behavioural Pharmacology 20(1) (February 2009): 84-98. Copyright 2009, Wolters Kluwer Health/Lippincott, Wil-
liams & Wilkins. Used by permission. DOI: 10.1097/FBP.0b013e3283243008.
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The rat conditioned avoidance response model is a well-established preclinical behavioral model predictive of antipsychotic 
efficacy. All clinically approved antipsychotic drugs disrupt conditioned avoidance responding – a feature that distinguishes 
them from other psychotherapeutics. We previously showed that the typical antipsychotic drug haloperidol disrupts avoidance 
responding by progressively attenuating the motivational salience of the conditioned stimulus (CS) in normal rats. In this study, 
using two pharmacological rat models of schizophrenia [e.g. phencyclidine (PCP) or amphetamine sensitization], we exam-
ined whether atypicals such as olanzapine or risperidone disrupt avoidance responding through the same behavioral mecha-
nism. Rats were first pretreated with PCP, amphetamine, or saline under one of two different injection schedules for either 1 or 
3 weeks. They were then trained to acquire avoidance responding to two types of CS (CS1 and CS2) that differed in their ability 
to predict the occurrence of the unconditioned stimulus. Finally, rats were tested repeatedly under olanzapine (1.0 mg/kg, sub-
cutaneously) or risperidone (0.33 mg/kg, subcutaneously) daily for 5 or 7 consecutive days. We found that repeated olanzapine 
or risperidone treatment produced a progressive across-session decline in avoidance responding to both CS1 and CS2. Olanzap-
ine and risperidone disrupted the CS2 (a less salient CS) avoidance to a greater extent than the CS1 avoidance. Pretreatment with 
PCP and amphetamine did not affect the disruptive effect of olanzapine or risperidone on avoidance responding. On the basis 
of these findings, we suggest that the atypical drugs olanzapine and risperidone, like the typical drug haloperidol, also disrupt 
avoidance responding primarily by attenuating the motivational salience of the CS.
Introduction
The rat conditioned avoidance response (CAR) is an aver-
sively motivated conditioned instrumental response in 
which animals are trained to make an active motor response 
to avoid footshock. In a typical CAR experiment, a rat is 
placed in a two-compartment shuttle box and presented with 
a conditioned stimulus (CS, e.g. white noise), followed by an 
aversive unconditioned stimulus (US, e.g. footshock). After 
several CS–US pairings, the rat typically runs from one com-
partment to another during the CS (before the onset of the 
US), hence, avoiding the US.
In behavioral pharmacology, the rat CAR model is com-
monly used as a preclinical test for antipsychotic efficacy 
(Arnt, 1982). It is generally found that rats treated with low 
doses (noncataleptic) of antipsychotic drugs (APDs) fail to 
acquire or perform avoidance responses to the CS, whereas 
their escape responses to the US are not affected (Ader and 
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deficit (Tenn et al., 2003), hypofrontal function and atten-
tional set-shifting deficit (Fletcher et al., 2005; Tenn et al., 
2005), and social interaction deficit (Sams-Dodd, 1998b). To 
explore the possible motivational salience attenuation mech-
anism, we used a modified avoidance conditioning proce-
dure involving two types of CS (CS1 and CS2) that varied in 
their salience and ability to predict the occurrence of the US. 
If OLZ and RIS disrupt avoidance responding by selectively 
attenuating the motivational salience of the CS, we expected 
that both drugs would have a stronger disruptive effect on a 
less salient CS (CS2)-elicited avoidance than a highly salient 
CS (CS1)-elicited one.
Methods
Subjects
Male Sprague–Dawley rats (226-250 g upon arrival, 
Charles River, Portage, Michigan, USA) were housed two 
per cage, in 48.3 × 26.7 × 20.3cm transparent polycarbonate 
cages under 12-h light/dark conditions (light on between 
06.30 and 18.30 h). Room temperature was Maintained at 21 
± 11°C with a relative humidity of 55-60%. Food and water 
were freely available. Animals were allowed at least 1 week 
of habituation to the animal facility before being used in 
experiments. All procedures were approved by the Institu-
tional Animal Care and Use Committee at the University of 
Nebraska-Lincoln.
Avoidance conditioning apparatus
Six identical two-way shuttle boxes custom designed and 
manufactured by Med Associates (St. Albans, Vermont, 
USA) were used. Each box was housed in a ventilated, 
sound-insulated isolation cubicle (96.52 cm wide × 35.56 
cm deep × 63.5 cm high). Each box was 64 cm long, 30 cm 
high (from grid floor), and 24 cm wide, and was divided 
into two equal-sized compartments by a partition with an 
arch style doorway (15 cm high × 9 cm wide at base). A bar-
rier (4 cm high) was placed between the two compartments, 
and therefore the rats had to jump from one compartment to 
the other. The grid floor consisted of 40 stainless-steel rods 
with a diameter of 0.48 cm, spaced 1.6 cm apart center to 
center, through which a scrambled footshock (US, 0.8 mA; 
maximum duration: 5 s) was delivered by a constant current 
shock generator (Model ENV-410B) and scrambler (Model 
ENV-412). Illumination was provided by two houselights 
mounted at the top of each compartment. The CSs [either a 
76 dB white noise (CS1) or a 85 dB 2800 Hz pure tone (CS2)] 
were produced by a speaker (ENV-224 AMX) mounted on 
the ceiling of the cubicle, centered above the shuttle box. 
Background noise (approximately 74 dB) was provided by 
a ventilation fan affixed at the top corner of each isolation 
cubicle. All training and testing procedures were controlled 
by Med Associates programs running on a computer.
We recently used the CAR model based on a repeated 
treatment regimen and examined the behavioral mecha-
nisms of antipsychotic action in this model (Li et al., 2007). 
We found that rats treated with haloperidol (HAL) and 
tested daily for 7 consecutive days showed a progressive 
across-session decline in avoidance responding, suggesting 
that HAL may disrupt avoidance responding by progres-
sively attenuating the motivational salience of the CS (Wise, 
2004). We also found that HAL-treated rats tested under a 
40-trial testing session showed a faster decline than those 
tested under a 10-trial session, which in turn showed a faster 
decline than those tested under a 3-trial session. These data, 
together with our early study showing that rats previously 
treated with HAL still exhibit decreased avoidance behav-
ior in the later drug-free tests (Li et al., 2004), are suggested 
to reflect the weakening effect of the drug on the motiva-
tional salience of the CS. On the basis of these findings, we 
proposed that one possible mechanism by which APDs dis-
rupt avoidance responding is to decrease the motivational 
salience of the CS or incentive motivation of rats to respond 
to the CS.
As the experiments described above were done primarily 
by using the typical antipsychotic HAL, whether the same 
behavioral mechanism is also responsible for the effects of 
atypical antipsychotics, such as olanzapine (OLZ) or risperi-
done (RIS), has not been tested and is still unknown. Because 
of the unique receptor-binding profile associated with each 
APD (Kapur and Remington, 2001), it is possible that they 
may work differently than HAL in the CAR model. Further-
more, subjects used in that study were normal rats, while 
antipsychotics are usually used to treat patients with schizo-
phrenia. Whether antipsychotics work in the same way in 
putative rat models of schizophrenia has not been investi-
gated. There is a possibility that these two functionally dif-
ferent populations might respond differently to antipsy-
chotic treatment in the CAR model. Therefore, the primary 
goal of this study was to investigate the behavioral mecha-
nism underlying the decrease in avoidance responding effect 
of OLZ and RIS in putative animal models of schizophrenia. 
Specifically, we sought to determine (i) whether OLZ and 
RIS, the two most widely prescribed atypical antipsychot-
ics at the therapeutic relevant doses [approximately 65–80% 
striatal D2 occupancy in rodents (Kapur et al., 2003)], pro-
duce a similar progressive across-session decline in avoid-
ance responding in putative rat models of schizophrenia 
[e.g. amphetamine (AMPH) pretreated or phencyclidine 
(PCP) pretreated]; and (ii) to what extent repeated OLZ and 
RIS treatment suppresses avoidance responding by attenu-
ating motivational salience of the CS in the CAR model.
We chose AMPH-pretreated or PCP-pretreated rats as 
animal models of schizophrenia because they mimic many 
aspects of the illness at multiple levels, such as hyperdop-
aminergic (Robinson and Becker, 1986) and hypoglutamater-
gic activity (Jentsch and Roth, 1999), prepulse inhibition def-
icit (Geyer et al., 2001; Russig et al., 2003), latent inhibition
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Experiment 2: Effect of repeated OLZ treatment on CS1 and 
CS2 avoidance in AMPH-pretreated rats
We adopted a widely used AMPH treatment schedule 
that is shown to be effective in inducing deficits in prepulse 
inhibition or latent inhibition resembling those observed in 
patients with schizophrenia (Murphy et al., 2001; Pezze et al., 
2002; Russig et al., 2002; Peleg-Raibstein et al., 2006; Peleg-
Raibstein and Feldon, 2008). Forty-two rats received three 
daily i.p. injections of either d-amphetamine sulfate (n = 22, 
AMPH at 1-5 mg/ml/kg) or 0.9% saline (n = 20, saline at 
1 ml/kg). Injections were administered at 07.00, 13.00, and 
19.00 h over a 6-day period. On day 1, the three AMPH injec-
tion doses were 1, 2, and 3 mg/kg in this escalating order. On 
day 2, the first AMPH injection dose was 4.0 mg/kg, and the 
remaining two were 5.0 mg/kg. From days 3-6, each AMPH 
injection dose was always 5.0 mg/kg. The saline injection 
volume was always 1 ml/kg.
The remainder of the experiment was similar to experiment 
1. First, rats were trained to acquire avoidance responding to 
the CS1 and CS2. At the end of the training phase, only 12 
AMPH-treated rats and 10 saline-treated rats had reached 
the training criterion (≥ 14 CS1 avoidances and at least one 
CS2 avoidance in the last two training sessions). Thus, we 
gave all rats one additional training session to boost their 
performance. They were then randomly assigned to two sub-
groups and subjected to 7 days of OLZ tests. Four experi-
mental groups were formed on the basis of pre-drug treat-
ment (AMPH vs. VEH) and antipsychotic treatment (OLZ vs. 
VEH): AMPH-VEH (n = 4), AMPH–OLZ (n = 8), VEH-VEH 
(n = 4), and VEH-OLZ (n = 6). During each daily test, rats 
were injected with OLZ (1.0 mg/kg) or VEH (sterile water) 
s.c. 1 h before testing. The same procedure used during train-
ing was used for the drug testing.
Experiment 3: Replication study of the effect of repeated 
OLZ treatment on CS1 and CS2 avoidance in AMPH-pre-
treated rats
In experiment 2, only 22 rats out of 42 (52%) reached the 
training criterion, which was much lower compared with the 
30 rats from experiment 1 (71%). Our past experience sug-
gests that under most circumstances, approximately 70-75% 
of rats trained in this task reach this criterion; thus, the lower 
percentage of rats reaching the training criterion might sug-
gest that rats in experiment 2 did not adequately represent 
a valid sample of the rat population under study. Conse-
quently, in experiment 3, we tried to replicate experiment 2 
using a new batch of rats. The basic procedure was identi-
cal to that of experiment 2 except that rats were only tested 
for four OLZ sessions, instead of seven, because we noticed 
that after four OLZ sessions, avoidance responding gener-
ally reached a minimum. In this experiment, 28 rats out of 
42 (67%) eventually reached the training criterion (≥ 14 CS1 
avoidances and at least one CS2 avoidance in the last two 
training sessions), and their grouping information was as fol-
lows: AMPH–VEH (n = 8), AMPH–OLZ (n = 8), VEH–VEH 
(n = 7), and VEH–OLZ (n = 5).
Locomotor activity apparatus 
Sixteen activity boxes were housed in a quiet room. The 
boxes were 48.3 × 26.7 × 20.3 cm transparent polycarbonate 
cages, which were similar to the home cages but were each 
equipped with a row of six photocell beams (7.8 cm between 
two adjacent photobeams) placed 3.2 cm above the floor of 
the cage. A computer detected the disruption of the photocell 
beams and recorded the number of beam breaks. All experi-
ments were run during the light cycle.
Experiment 1: Effect of repeated OLZ treatment on CS1 and 
CS2 avoidance in PCP-pretreated rats 
Forty-two rats were injected with PCP [n=22, 5 mg/kg 
intraperitoneally (i.p.)] or vehicle (VEH) (n=20) twice daily 
for 7 days. The two injections were separated by 12 h. This 
PCP sensitization regimen has been widely used and is 
shown to induce a decrease in prefrontal dopaminergic utili-
zation, augmented motor activity, and various cognitive def-
icits (Jentsch et al., 1997; Jentsch and Taylor, 2001; Rodefer 
et al., 2005; Dunn and Killcross, 2006). After a 5-day period 
of withdrawal (the drug-free period), rats were habituated 
to the shuttle box for 2 days (30 min/day). Rats were then 
trained daily in a modified two-way avoidance conditioning 
task for a total of 10 sessions. Each training session consisted 
of 30 trials. Twenty trials (CS1 trials) used a 10 s 76 dB white 
noise as the CS with its termination immediately followed 
by the shock (0.8 mA; maximum duration: 5 s) if the rats did 
not make an avoidance response; thus, it was a highly salient 
and perfect predictor of the US. The remaining 10 trials (CS2 
trials) used a pure tone (10 s, 2800 kHz, 85 dB) as the CS. In 
half of the CS2 trials (five trials), the CS2 was followed by the 
shock if the rat failed to respond to the CS2; whereas, in the 
other half, it was not; thus, it was a less salient and less infor-
mative signal compared with the CS1. The 20 CS1 trials were 
randomly intermixed with the 10 CS2 trials. During each 
trial, if a subject moved from one compartment into the other 
within the 10 s of CS presentation, the CS was immediately 
terminated and the shock was prevented, and this shuttling 
response was recorded as avoidance (termed CS1 avoidance 
or CS2 avoidance). If the rat remained in the same compart-
ment for more than 10 s and made a crossing upon receiv-
ing the footshock, this response was recorded as escape. If 
the rat did not respond during the entire 5 s presentation of 
the shock, the trial was terminated and escape failure was 
recorded.
After training, 16 rats from the PCP group and 14 from the 
VEH group had achieved a high level of avoidance respond-
ing (≥ 14 CS1 avoidances and at least one CS2 avoidance in 
the last two training sessions). Each group was then ran-
domly assigned to two subgroups and underwent 7 consec-
utive days of repeated OLZ or VEH testing. This resulted in 
four experimental groups: PCP-VEH (n = 8), PCP–OLZ (n = 
8), VEH-VEH (n = 7), and VEH-OLZ (n = 7). On each test 
day, rats were injected with OLZ (1.0 mg/kg) or VEH (sterile 
water) subcutaneously (s.c.) 1 h before testing. The same pro-
cedure used during training was used for the drug testing.
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or 0.9% saline 1 h before testing. One day after the end of the 
seventh test, the previous three VEH groups were switched 
to OLZ (1.0 mg/kg) and further tested for another five ses-
sions. This add-on experiment was intended to assess fur-
ther the effect of PCP and AMPH pretreatment on the effect 
of OLZ.
Drugs
The injection solutions of d-amphetamine sulfate (AMPH, 
Sigma-RBI, Natick, Massachusetts, USA) and phencycli-
dine hydrochloride (PCP; gift from the National Institute 
on Drug Abuse Chemical Synthesis and Drug Supply Pro-
gram and Sigma-Aldrich, St. Louis, Missouri, USA) were 
obtained by mixing drugs with 0.9% saline. OLZ (Toronto 
Research Chemical Inc., North York, Canada) and RIS (gift 
from NIMH Chemical Synthesis and Drug Supply Program) 
were dissolved in 1.5% glacial acetic acid in distilled water. 
We chose OLZ at 1.0 mg/kg and RIS at 0.33 mg/kg because 
they are effective in producing a progressive across-session 
decrease in avoidance responding in normal rats (Li et al., 
2007), and both drugs at these doses give rise to clinically 
comparable levels of striatal D2 occupancy (60-70%) (Kapur 
et al., 2003).
Statistical analysis
CS1 and CS2 avoidance response data from the training 
phase were expressed as mean values ± SEM and were ana-
lyzed using a factorial repeated-measures analysis of vari-
ance (ANOVA) with the between-subjects factor being ‘pre-
treatment’ (PCP, AMPH, or VEH) treatment condition and 
the within-subject factors being the test sessions (‘session’) 
and types of trials (e.g. ‘type’: CS1 avoidance or CS2 avoid-
ance).
Each rat’s avoidance performance on each drug test session 
was expressed as the percent avoidance relative to its own 
value on the last training (10th) day (except in experiment 4, 
where data from the 9th training day were used for all rats) 
to account better for the differences in CS1 (maximum: 20 tri-
als) and CS2 (maximum: 10) avoidances at the baseline. Data 
were analyzed using a factorial repeated-measures ANOVA 
with the between-subjects factors being ‘pretreatment’ (PCP, 
AMPH, or VEH) and ‘drug’ treatment condition (OLZ, RIS, 
or VEH) and the within-subject factors being the test sessions 
(‘session’) and types of trials (e.g. ‘type’: CS1 avoidance or 
CS2 avoidance). Two-group comparisons were tested using 
post-hoc Tukey tests. A conventional two-tailed level of sig-
nificance at the 5% level was required.
For the locomotor activity data from experiment 4, the 
number of photobeam breaks was expressed as mean values 
± SEM and analyzed using repeated-measures ANOVA with 
the pretreatment condition (PCP, AMPH, or VEH) and the 
challenge drugs (PCP or AMPH) as the between-subjects fac-
tors and the 5-min time block (‘block’) as the within-subjects 
factor. Two-group comparison was done using independent 
samples t-tests.
Experiment 4: Effect of repeated RIS and OLZ treatment on 
CS1 and CS2 avoidance in PCP-pretreated and AMPH-pre-
treated rats
In experiment 4, we used different PCP and AMPH treat-
ment regimens to examine effects of repeated RIS and OLZ 
treatment on CS1 and CS2 avoidance in both PCP-pretreated 
and AMPH-pretreated rats. This experiment was done not 
only to replicate the findings from the above three experi-
ments, but also to examine the generalization issue to ensure 
that they can be extended to other PCP and AMPH models 
of schizophrenia. As PCP and AMPH pretreatments were 
done in the same batch of rats, this experiment also allowed 
us to directly compare any possible differential effect of PCP 
or AMPH pretreatment on RIS-induced and OLZ-induced 
decrease in avoidance responding. Sixty rats were randomly 
assigned to one of three groups (n = 20), with each rat receiv-
ing an s.c. injection of d-amphetamine sulfate (1.0-3.0 mg/
kg), PCP (3.0 mg/kg), or 0.9% saline (1.0 ml/kg) three times 
per week for 3 weeks for a total of nine injections. The AMPH 
dose increased from 1.0–3.0 mg/kg, at the rate of 1 mg/kg 
each week. The PCP dose remained at 3.0 mg/kg through-
out. This sensitization schedule for PCP and AMPH has been 
used by Tenn et al. (2005) who showed that it can produce a 
strong PCP and AMPH sensitization effect and that AMPH 
sensitization induces prepulse inhibition and latent inhibi-
tion deficits. After 18 days withdrawal from PCP and AMPH 
pretreatment, we assessed the AMPH and PCP pretreatment 
effect (e.g. behavioral sensitization effect). All rats were habit-
uated to the locomotor activity apparatus for 30 min/day for 
2 consecutive days. On day 3, rats were placed in the locomo-
tor activity apparatus for 10 min, and then they were taken 
out and injected with either AMPH at 0.5 mg/kg or PCP 
at 1.5 mg/kg and immediately placed back into the appa-
ratus for another 60 min. Half of the rats from each group 
(n = 10) were injected with AMPH, whereas the other half 
(n = 10) were injected with PCP. Locomotor activity (num-
ber of photobeam breaks) was measured in 5 min blocks for 
the entire 60-min testing session. One day later, the training 
phase consisting of 10 sessions started. The basic procedure 
was the same as described in the first three experiments with 
one slight modification. Halfway through the training phase 
(after the fifth session), we removed the eight rats which had 
the lowest avoidance responses on that day (one from PCP, 
five from the AMPH group, and two from the VEH group) 
from further training to eliminate unnecessary pain and 
stress, because they would most likely not reach the training 
criterion based on our experience. On the last (10th) training 
day, because of an unknown technical issue, data from eight 
rats were lost, and we thus used the data from the eighth 
and ninth training sessions to identify those that reached the 
training criterion (≥ 14 CS1 avoidances and at least one CS2 
avoidance in the last two training sessions). Forty-five rats 
(75% of a total of 60 rats) were identified and were repeat-
edly tested daily for 7 days under either RIS or VEH. The fol-
lowing six experimental groups were formed: PCP-VEH (n = 
8), PCP–RIS (n = 8), AMPH-VEH (n = 7), AMPH-RIS (n = 6), 
VEH-VEH (n = 8), and VEH-RIS (n = 8). During each daily 
test, rats received an s.c. injection of either RIS (0.33 mg/kg) 
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gressive decline in both CS1 and CS2 avoidances. Repeated-
measures ANOVA indicated that there were significant main 
effects of ‘session’ [F(6,156) = 6.34, P < 0.001] and ‘drug’ [F(1,26) = 
82.12, P < 0.001], and a significant ‘session’ × ‘drug’ interac-
tion [F(6,156) = 5.10, P < 0.001]. In addition, it seems that OLZ 
had a stronger disruptive effect on the CS2 avoidance than 
CS1 avoidance as it caused a sharper decline in the CS2 avoid-
ance than the CS1 avoidance relative to the baseline (Figure 
1). Statistical analysis confirmed this observation. There was 
a significant effect of ‘type’ × ‘drug’ interaction [F(1,26) = 6.65, 
P < 0.02]. Pretreatment with PCP did not seem to signifi-
cantly change the effect of OLZ, as there was no significant 
main effect of ‘pretreatment’ [F(1,26) = 0.83, NS] and no signif-
icant interactions involving ‘pretreatment’ and other factors 
(all P values > 0.37).
Experiment 2: Effect of repeated OLZ treatment on CS1 and 
CS2 avoidance in AMPH-pretreated rats
Throughout the 11 training sessions, rats from both groups 
(AMPH-pretreated or VEH-pretreated) showed a similar 
learning effect, as evidenced by the progressive increase in 
the number of CS1 and CS2 avoidance responses across ses-
sions (data not shown). Repeated-measures ANOVA indi-
cated that there were significant main effects of ‘session’ 
[F(10,400) = 19.09, P < 0.001] and ‘type’ [F(1,40) = 96.61, P < 0.001], 
but no significant main effect of ‘pretreatment’ [F(1,40) = 0.170, 
NS] or ‘type’ × ‘pretreatment’ and ‘session’ × ‘pretreatment’ 
interactions (all P values > 0.40). Once again, the acquisi-
tion of CS1 avoidance was faster than the acquisition of 
CS2 avoidance [‘type’ × ‘session’ interaction, F(10,400) = 10.52, 
Results
Experiment 1: Effect of repeated OLZ treatment on CS1 and 
CS2 avoidance in PCP-pretreated rats
One rat from the VEH group died before the completion 
of training. Its data were excluded from further analysis. 
Throughout the 10 training sessions, rats from both groups 
(PCP-pretreated or VEH-pretreated) showed a similar learn-
ing effect, as evidenced by the progressive increase in the 
number of CS1 and CS2 avoidance responses across sessions 
(data not shown). Repeated-measures ANOVA indicates that 
there were significant main effects of ‘session’ [F(9,351) = 28.80, 
P < 0.001] and ‘type’ [F(1,39) = 200.90, P < 0.001], but no signifi-
cant main effect of ‘pretreatment’ [F(1,39) = 0.123, NS] or ‘type’ 
× ‘pretreatment’ and ‘session’ × ‘pretreatment’ interactions 
(all P values > 0.75). The acquisition of CS1 avoidance was 
faster than the acquisition of CS2 avoidance [‘type’ × ‘ses-
sion’ interaction, F(9,351) = 13.01, P < 0.001], a result that was 
expected from the experimental design in which only half of 
the CS2 trials were followed by shock, whereas all the CS1 
trials were followed by shock if the rats failed to respond. 
Table 1 summarizes the mean numbers and percentages of 
avoidance response to CS1 and CS2 on the last training ses-
sion for rats that reached the training criterion. No signifi-
cant group difference on these measures was found (all P 
values > 0.05).
During the OLZ testing phase, the VEH-treated rats 
maintained their training levels of CS1 and CS2 avoidance 
throughout the sessions, whereas the OLZ rats showed a pro-
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ANOVA indicated that there were significant main effects of 
‘session’ [F(6,108) = 8.129, P <0.001] and ‘drug’ [F(1,18) = 49.107, 
P < 0.001], and a significant ‘session’ × ‘drug’ interaction 
[F(6,108) = 3.91, P < 0.001]. Unlike the findings from experi-
ment 1, OLZ did not show a stronger disruptive effect on the 
CS2 avoidance than the CS1 avoidance (Figure 2), as there 
was neither a significant main effect of  ‘type’ [F(1,18) = 2.29, 
NS], nor a significant ‘type’ ×‘drug’ interaction [F(1,18) = 1.42, 
NS]. Pretreatment with AMPH did not seem to significantly
P < 0.001]. There were no significant group differences in the 
mean numbers and percentages of CS1 and CS2 avoidances 
on the last training session of the rats that reached the train-
ing criterion (all P values > 0.05, Table 1). 
During the OLZ testing phase, the VEH-treated rats main-
tained their training levels of CS1 and CS2 avoidance through-
out the sessions, whereas the OLZ rats showed a progressive 
decline in both CS1 and CS2 avoidances. Repeated-measures 
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learning effect throughout the 10 training sessions, as evi-
denced by the progressive increase in the number of CS1 and 
CS2 avoidance responses across sessions (data not shown). 
Repeated-measures ANOVA indicated that there were sig-
nificant main effects of ‘session’ [F(9,360) = 32.48, P < 0.001] and 
‘type’ [F(1,40) = 171.38, P < 0.001], but no significant main effect 
of ‘pretreatment’ [F(1,40) = 0.12, NS] or ‘type’ × ‘pretreat-
ment’ and ‘session’ × ‘pretreatment’ interactions (all P val-
ues > 0.83). Once again, the acquisition of CS1 avoidance was 
faster than the acquisition of CS2 avoidance [‘type’ ×‘session’ 
interaction, F(9,360) = 15.03, P < 0.001]. There were no signifi-
change the effect of OLZ, as there was no significant main 
effect of ‘pretreatment’ [F(1,18) = 0.656, NS] and no significant 
interaction involving ‘pretreatment’ and other factors (all P 
values > 0.08). 
Experiment 3: Replication study of the effect of repeated 
OLZ treatment on CS1 and CS2 avoidance in AMPH-pre-
treated rats
Similar to what was seen in experiment 2, rats from both 
groups (AMPH-pretreated or VEH-pretreated) showed a
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avoidance relative to the baseline (Figure 3). Statistical anal-
ysis confirmed this observation [‘type’ × ‘drug’ interaction: 
F(1,24) = 6.85, P < 0.02]. Similar to experiment 2, pretreatment 
of AMPH did not significantly change the effect of OLZ, as 
there was no significant main effect of ‘pretreatment’ [F(1,24) = 
0.058, NS] and no significant interaction involving ‘pretreat-
ment’ and other factors (all P values > 0.11).
Experiment 4: Effect of repeated RIS and OLZ treatment on 
CS1 and CS2 avoidance in PCP-pretreated and AMPH-pre-
treated rats
After 3 weeks of withdrawal from PCP and AMPH treat-
ment, all rats were tested for locomotor activity after an acute 
injection of PCP (1.5 mg/kg, s.c.) or AMPH (0.5 mg/kg, s.c.) 
cant group differences in the mean numbers and percentages 
of CS1 and CS2 avoidances on the last training session for 
rats that reached the training criterion (all P values > 0.05, 
Table 1).
During the OLZ testing phase, the VEH-treated rats main-
tained their training levels of CS1 and CS2 avoidance through-
out the sessions, whereas the OLZ rats showed a progressive 
decline in both CS1 and CS2 avoidances. Repeated-measures 
ANOVA indicates that there were significant main effects of 
‘session’ [F(3,72) = 5.63, P < 0.002] and ‘drug’ [F(1,24) = 121.53, P < 
0.001], and a significant effect of ‘session’ × ‘drug’ interaction 
[F(3,72) = 5.09, P < 0.005]. In addition, OLZ had a stronger dis-
ruptive effect on the CS2 avoidance than CS1 avoidance as it 
caused a sharper decline in the CS2 avoidance than the CS1
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and the ‘challenge drugs’ (PCP or AMPH) as the between-
subjects factors and the 5-min time block (‘block’) as the 
within-subjects factor indicated that there was a significant
for 60 min (12 5-min blocks) to assess the behavioral sensiti-
zation effect (Figure 4a and b).  Repeated-measures ANOVA 
with the ‘pretreatment’ condition (PCP, AMPH, or VEH) 
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ances regardless of pretreatment (Figure 5a-c). Repeated-
measures ANOVA indicated that there were significant 
main effects of ‘session’ [F(6,234) = 2.19, P < 0.05], ‘drug’ [F(1,39) 
= 48.44, P <0.001], and a significant three-way ‘session’ × 
‘drug’ × ‘pretreatment’ interaction [F(12,234) = 1.81, P < 0.05]. 
In addition, RIS had a stronger disruptive effect on the CS2 
avoidance than CS1 avoidance. There was a significant ‘type’ 
×  ‘drug’ interaction [F(1,39) = 6.38, P <0.02]. Pretreatment with 
PCP and AMPH did not seem to alter the effect of RIS, as 
there was no significant main effect of ‘pretreatment’ [F(2,39) = 
0.97, NS] and no significant ‘pretreatment’ and ‘drug’ inter-
action [F(2,39) = 2.04, NS]. 
During the OLZ testing phase, rats previously tested 
under VEH were switched to OLZ and further tested for 
five sessions (Figure 6). Similar to results from the first three 
experiments, the OLZ rats showed a progressive decline in 
both CS1 and CS2 avoidances across sessions in compari-
son with their avoidance performance on the last VEH ses-
sion. Repeated-measures ANOVA indicated that there was 
a significant main effect of ‘session’ [F(4,80) = 5.05, P < 0.001]. 
In addition, OLZ had a stronger disruptive effect on the 
CS2 avoidance than CS1 avoidance as there was a signifi-
cant main effect of ‘type’ [F(1,20) = 17.46, P < 0.001]. Pretreat-
ment with PCP or AMPH did not significantly change the 
effect of OLZ, as there was no significant main effect of ‘pre-
treatment’ [F(2,20) = 0.94, NS] and no significant interactions 
involving ‘pretreatment’ and other factors (all P values > 
0.14).
Discussion
This study examined the behavioral mechanism of the 
atypical antipsychotics OLZ and RIS in the CAR model in 
PCP-pretreated and AMPH-pretreated rats, two widely 
used putative animal models of schizophrenia. We used a 
modified avoidance response task in which two different 
salient CS signals were used to elicit avoidance response, 
and found that both OLZ and RIS produced a progressive 
decrease in avoidance responding across sessions in drug 
naive, as well as PCP-pretreated and AMPH-pretreated rats, 
confirming and extending our previous findings (Li et al., 
2007). More importantly, we found that OLZ and RIS prefer-
entially disrupted a less salient CS (CS2)-elicited avoidance 
to a highly salient CS (CS1)-elicited avoidance, a finding 
that is consistent with the view that antipsychotics disrupt 
avoidance responding primarily by selectively attenuat-
ing the motivational salience of the CS (Li et al., 2007). Fur-
thermore, we did not find any consistent effect of PCP and 
AMPH pretreatment on the decrease in avoidance respond-
ing elicited by OLZ and RIS, suggesting that behavioral 
action of antipsychotics operates similarly in different pop-
ulations of subjects.
main effect of ‘challenge drugs’ [F(1,54) = 33.62, P < 0.001] and 
a significant ‘challenge drugs’ × ‘pretreatment’ interaction 
[F(2,54) = 8.64, P < 0.001]. Overall, AMPH caused a significantly 
higher increase in the number of photobeam breaks than did 
PCP. This effect was more pronounced in the AMPH-pre-
treated and VEH-pretreated rats than in the PCP-pretreated 
ones. Over the 60-min testing period, there was a significant 
main effect of ‘block’ [F(11,594) = 33.39, P <0.001] and signifi-
cant interactions between ‘block’ and ‘pretreatment’ [F(22,594) 
= 4.12, P < 0.001], ‘block’ and ‘challenge drugs’ [F(11,594) = 
5.16, P < 0.001], and ‘block’, ‘pretreatment’, And ‘challenge 
drugs’ [F(22,594) = 33.62, P <0.002]. Inspection of Figure 4b sug-
gests that PCP pretreatment significantly potentiated the 
effect of challenge treatment of PCP, as the PCP-pretreated 
rats showed a significantly higher increase in the number of 
photobeam breaks than the AMPH-pretreated or VEH-pre-
treated rats. However, the AMPH pretreatment effect was 
less obvious, as 0.5 mg/kg dose of AMPH caused a simi-
lar level of increase in motor activity in AMPH-pretreated 
and VEH-pretreated groups, an effect independent of pre-
treatment conditions; thus, the potential AMPH sensitiza-
tion effect might be masked. For the total activity counts 
(Figure 4c), two-group comparisons indicate that under the 
AMPH challenge, the PCP-pretreated group showed a sig-
nificantly lower increase in motor activity than the other 
two groups (all P values < 0.029); whereas under the PCP 
challenge, the PCP-pretreated group showed a significantly 
higher increase in motor activity than the other groups (all 
P values < 0.05).
Fifty-two rats finished all 10 training sessions. They 
showed a similar level of learning, as evidenced by the pro-
gressive increase in the number of CS1 and CS2 avoidance 
responses across sessions (data not shown). Repeated-mea-
sures ANOVA indicated that there were significant main 
effects of ‘session’ [F(9,279) = 34.80, P < 0.001] and ‘type’ [F(1,31) 
= 3036.12, P < 0.001] but no significant main effect of ‘pre-
treatment’ [F(2,31) = 0.97, NS] or ‘type’ × ‘pretreatment’ and 
‘session’ × ‘pretreatment’ interactions (all P values > 0.085). 
The acquisition of CS1 avoidance was faster than the acqui-
sition of CS2 avoidance [‘type’ × ‘session’ interaction, F(1,31) 
= 3036.12, P < 0.001], a result that was expected from the 
experimental design in which only half of the CS2 trials 
were followed by shock, whereas all the CS1 trials were fol-
lowed by shock if the rats failed to respond. There were no 
significant group differences in the mean numbers and per-
centages of CS1 and CS2 avoidances on the last training ses-
sion for rats that reached the training criterion (all P values 
> 0.05, Table 1).
During the RIS testing phase, the VEH-treated rats 
maintained their training levels of CS1 and CS2 avoid-
ance throughout the sessions, whereas the RIS-treated rats 
showed a progressive decline in both CS1 and CS2 avoid-
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shock) under different schedules of reinforcement (a fixed-
interval schedule or a multiple schedule with alternating 
fixed-ratio and fixed-interval components) (Spealman et al., 
1983). To distinguish between these two alternative inter-
pretations (‘‘motivational salience’’ versus ‘‘different base-
line response’’), it is ideal to create a condition in which 
CS1 and CS2 avoidance have equivalent baselines but dif-
ferent motivational saliencies or have equivalent motiva-
tional saliencies but different baselines. One way to achieve 
this is to make the number of CS2-shock pairings equal to 
the number of CS1-shock pairings but to maintain the per-
centage of CS2 and CS1 trials followed by shock at 50% and 
100% respectively (i.e., the total number of CS2 trials are 
twice the number of CS1 trials). Under this condition, the 
baselines of CS1 and CS2 avoidance will be similar, but CS1 
will still be more salient than CS2 due to the fact that it will 
be paired with shock to a greater proportion of its presen-
tations than CS2. If the motivational salience interpretation 
is correct, we expect that antipsychotics would still decrease 
CS2 avoidance to a greater extent than CS1 avoidance. On 
the other hand, if the different baseline interpretation is cor-
rect, we expect that antipsychotics would decrease CS1 and 
CS2 avoidance to a similar extent. Future work is needed to 
determine the relative validity of each interpretation.
In this study, we also examined whether antipsychotics 
disrupt avoidance responding in putative animal models of 
schizophrenia in the same way as in normal animals. This 
was done by using two widely used pharmacological mod-
els of schizophrenia, AMPH sensitization, and PCP sensiti-
zation (Robinson and Becker, 1986; Xu and Domino, 1994; 
Phillips et al., 2001; Castner et al., 2005; Featherstone et al., 
2007). It is well known that repeated intermittent exposure 
to psychostimulants such as AMPH and dissociative anes-
thetics such as PCP can induce psychotic-like disorders very 
similar to psychosis observed in patients with schizophre-
nia (Bell, 1965; Janowsky and Risch, 1979; Javitt and Zukin, 
1991). Both classes of psychotomimetic drugs also exacerbate 
existing psychotic symptoms in acute patients with schizo-
phrenia (Itil et al., 1967; Snyder, 1973; Murray, 2002). Animals 
repeatedly treated with AMPH or PCP show an array of long-
lasting molecular, cellular, and behavioral changes similar 
to those observed in patients with schizophrenia (Robinson 
and Becker, 1986; Nestler, 2001; Martinez et al., 2005), such as 
behavioral sensitization (Segal and Mandell, 1974; Segal et 
al., 1981) and various psychological dysfunctions such as def-
icits in attention (Geyer et al., 2001; Tenn et al., 2005), work-
ing memory (Bruto et al., 1984; Jentsch et al., 1997; Jentsch and 
Anzivino, 2004; Marrs et al., 2005), behavioral flexibility and 
executive functioning (Jentsch and Taylor, 2001; Fletcher et 
al., 2005), and social interaction (Sams-Dodd, 1998a; Ellen-
broek and Cools, 2000). In this study, we used the AMPH 
and PCP treatment regimens that are commonly used in the 
literature (Jentsch et al., 1997; Jentsch and Taylor, 2001; Mur-
phy et al., 2001; Pezze et al., 2002; Russig et al., 2002; Rodefer 
et al., 2005; Dunn and Killcross, 2006; Peleg-Raibstein et al., 
2006; Peleg-Raibstein and Feldon, 2008), and found that OLZ 
and RIS had a similar effect in PCP-pretreated and AMPH-
Our previous study provides several pieces of evidence 
suggesting that HAL at noncataleptic and clinically rel-
evant doses (< 0.05 mg/kg, s.c, based on the striatal dop-
amine D2 occupancy data; (Kapur et al., 2003) disrupt avoid-
ance responding primarily by attenuating the motivational 
salience of the CS (Li et al., 2004, 2007). In other words, 
HAL is suggested to decrease the ability of the CS to elicit 
active motor response to terminate the CS and avoid the US 
(Beninger, 1989; Berridge and Robinson, 1998). In this study, 
we used a novel CAR task and asked whether or not atypi-
cal OLZ and RIS also disrupt avoidance responding by this 
mechanism. In this task, we created two types of CS signals 
(CS1 and CS2) that varied in their motivational salience (e.g. 
ability to elicit avoidance). This was achieved by pairing the 
CS1 with the US in every CS1 trial, whereas pairing the CS2 
with the US in only half of the CS2 trials if the rats failed to 
respond. In addition, we used more CS1 trials (20) than CS2 
trials (10) in each training/testing session. That the CS2 was 
rendered to be a less salient signal was reflected by the fol-
lowing two findings: first, at the end of training, the mean 
numbers and percentages of CS2elicited avoidances (4.08-
5.60 out of 10, or 40.8-56.0%) were much lower than CS1-
elicited ones (18.23-19.38 out of 20, or 91.1-96.9%) (Table 1); 
and second, rats acquired CS2 avoidance at a much slower 
rate than CS1 avoidance. As the sensory and motor func-
tions required to perform CS1 and CS2 avoidances are the 
same, the preferentially disruptive effect of OLZ and RIS 
on CS2 avoidance over CS1 avoidance cannot be attributed 
to their actions on sensory and motor functions, but rather 
indicates an action on incentive motivation of rats. In the 
CAR model, the ‘incentive motivation’ refers to the motiva-
tion instigated by a salient stimulus that drives organisms 
to actively pursue a safe environment or situation. Thus, 
HAL, OLZ, and RIS may disrupt avoidance responding by 
decreasing incentive motivation of rats to respond to the 
CS1 and CS2. This conceptualization of ‘incentive motiva-
tion’ is very similar to that of Salamone and Correa (2002), 
who suggest that low doses of dopamine antagonists, such 
as HAL, impair activational aspects of motivation, making 
animals less likely to engage in instrumental responses to 
obtain positive rewards. Alternatively, it is also possible that 
the differential drug effects on CS1 and CS2 avoidance may 
result from the different baseline levels of avoidance. On 
the last training day, the mean CS1 avoidance from all four 
experiments was about 95%, whereas the mean CS2 avoid-
ance was only 50%. This difference in avoidance responding 
rate at baseline may influence the magnitude of the disrup-
tive effects of APDs, independent of motivational salience 
of CS1 and CS2. In the literature, there are many illustra-
tions of this phenomenon that differences in scheduling of 
events and patterns of behavioral responding can deter-
mine the direction and magnitude of the behavioral effects 
of drugs (Dews, 1976; Spealman et al., 1983; Barrett, 2002; 
McMillan and Katz, 2002; Barrett et al., 2008). For example, 
it has been shown that under certain conditions, clozapine 
and chlordiazepoxide can decrease or increase a lever-press-
ing response (presentation of food, presentation of electric 
shock or termination of a stimulus associated with electric
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One caveat concerning this conclusion is that we only 
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nia. Kapur (2003) theorized that APDs work psychologically 
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This may lead to the almost immediate halt of the genera-
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RIS disrupt avoidance responding elicited by a weak stimu-
lus to a greater extent and at a faster rate than one elicited by 
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